ArticleFrontiers in oncology2020

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort.

Sheng-Kai Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.